CMMB实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	23 537.00
平均成交量	220 504
市值	9.09M
EPS	$0 ( 2024-03-07 )
下一个收益日期	( $-0.200 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.310
ATR14	$0.0120 (1.89%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-14	Darvish Nissim	Buy	20 572	Option to Purchase American Depositary Shares
2021-04-19	Darvish Nissim	Buy	11 884	Option to Purchase American Depositary Shares
2016-10-28	Darvish Nissim	Buy	10 123	Option to Purchase American Depositary Shares
2023-03-16	Darvish Nissim	Buy	6 857	Option to Purchase American Depositary Shares
2022-03-07	Darvish Nissim	Buy	6 820	Option to Purchase American Depositary Shares

INSIDER POWER
-57.70
Last 88 transactions
Buy: 2 375 207 \| Sell: 4 584 307

Anchiano Therapeutics Ltd 相关性

10 最正相关
SNGX	0.895
LAWS	0.894
NAKD	0.892
DTSS	0.891
CFMS	0.886
IMV	0.885
TNGX	0.883
PIXY	0.883
DBGI	0.875
MRNA	0.875

10 最负相关
SJ	-0.906
MLTX	-0.893
ACVA	-0.893
PEGA	-0.888
KIN	-0.886
TA	-0.885
NCAC	-0.883
CONX	-0.879
NEO	-0.877
MYNA	-0.876

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Anchiano Therapeutics Ltd 财务报表

Annual	2023
营收:	$0
毛利润:	$-66 827.00 (0.00 %)
EPS:	$-2.06

FY	2023
营收:	$0
毛利润:	$-66 827.00 (0.00 %)
EPS:	$-2.06

FY	2022
营收:	$0
毛利润:	$-57 773.00 (0.00 %)
EPS:	$-2.43

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.200

Financial Reports:

No articles found.

Anchiano Therapeutics Ltd

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.